JudithAbergMD(She/Her)

HIV/AIDS Medicine

Dean of System Operations for Clinical Sciences. The George Baehr Professor of Medicine. Chief, Division of Infectious Diseases

Join to view full profile

Dr. Aberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Aberg's full profile

Already have an account?

Office
1 Gustave L. Levy Place
Box 1090
New York, NY 10029
Phone+1 212-241-6741

Fax+1 212-534-3240

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Infectious Disease, 1994 - 1996
Cleveland Clinic FoundationChief Residency, Internal Medicine, 1993 - 1994
Cleveland Clinic FoundationResidency, Internal Medicine, 1990 - 1993
Pennsylvania State University College of MedicineClass of 1990

Certifications & Licensure

NY State Medical License 2003 - 2025
OH State Medical License 1991 - 2025
CA State Medical License 1996 - 2000
FL State Medical License 1992 - 1998
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly
Notable in Health Care 2020 Crain's New York Business, 2020
Empire Whole Health Heroes Award Crain's New York Business, 2020
Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2013-2016
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients
Completed
Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids
Completed
Phase 3
The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs
Completed
Phase 1
Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy Start of enrollment: 2005 May 01
Completed
Not Applicable
Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals
Completed
Phase 2
DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP) Start of enrollment: 2006 May 01
Terminated
Phase 3
Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy Start of enrollment: 2006 Sep 01
Completed
Phase 2, Phase 3
Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load Start of enrollment: 2009 Sep 01
Completed
Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications Start of enrollment: 2010 Sep 01
Completed
Phase 2
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells Start of enrollment: 2011 Apr 14
Completed
Phase 2
Modulation of Immune Activation by Aspirin Start of enrollment: 2014 Aug 01
Completed
Phase 2
A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults Start of enrollment: 2020 Dec 24
Completed
Phase 1
Outpatient Treatment With Anti-Coronavirus Immunoglobulin Start of enrollment: 2021 Aug 06
Recruiting
Phase 3
A Study of Ad26.COV2.S in Healthy Adults (COVID-19) Start of enrollment: 2021 May 25
Completed
Phase 1
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals Start of enrollment: 2020 Apr 29
Completed
Phase 2, Phase 3
To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. Start of enrollment: 2021 Jul 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

1594 citations
An inflammatory cytokine signature predicts COVID-19 severity and survival.
Diane Marie Del Valle, Seunghee Kim-Schulze, Hsin-Hui Huang, Noam D. Beckmann, Sharon Nirenberg
Nature Medicine. 2020-08-24
809 citations
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.
Ania Wajnberg, Fatima Amanat, Adolfo Firpo, Deena R. Altman, Mark J. Bailey
Science. 2020-12-04
55 citations
Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals
Mathieu Uzzan, Minami Tokuyama, Adam K. Rosenstein, Costin Tomescu, Ivo N. SahBandar
Science Translational Medicine. 2018-10-03

Lectures

2013 Interscience Conference On Antimicrobial Agents & Chemotherapy
American Society For Microbology, Denver, Colorado - 9/10/2013

Other

Nonoccupational exposure to HIV in adults
Aberg JA, Daskalakis D
http://www.uptodate.com/contents/nonoccupational-exposure-to-hiv-in-adults
UpToDate, Wolters Kluwer Health - 2013-02-07

Press Mentions

Biktarvy Could Be Long-Term Option for Older Adults With HIVOctober 6th, 2022
FDA Approves 2nd Booster Shots for Americans 50 and OlderMarch 30th, 2022
CDC Supports 2nd Booster Shots for Americans 50 and OlderMarch 30th, 2022
Join now to see all

Grant Support

New York University HIV/AIDS Clinical Trial UnitNational Institute Of Allergy And Infectious Diseases2007–2012
Virologic And Serologic Outcomes Of Persons With HIV And HBV Co-Infection On MonoNational Institute Of Allergy And Infectious Diseases2009–2010
Clinical Trial: ACTG A5241: Optimized Treatment That Includes Or Omits Nrtis (OpNational Center For Research Resources2008
Clinical Trial: ACTG A5229: Uridine Supplementation In HIV LipoatrophyNational Center For Research Resources2008
Clinical Trial: ACTG A5220: Using GM-CSF To Improve Immune Response To HepatitisNational Center For Research Resources2008
Clinical Trial: ACTG A5212: Palifermin For Inadequate CD4+ Lymphocyte RecoveryNational Center For Research Resources2008
Clinical Trial: ACTG A5211: SCH 417690 In Hiv-Infected, Treatment-Experienced SUNational Center For Research Resources2008
Clinical Trial: ACTG A5202: Efavirenz Or Atazanavir With Ritonavir In Arv-NaiveNational Center For Research Resources2008
Clinical Trial: ACTG A5197: Antiretroviral Effect Of Immunization With The MRK ANational Center For Research Resources2008
Clinical Trial: ACTG A5175: Once-Daily ARV Therapy For HIV-1 In Resource-LimitedNational Center For Research Resources2008
Clinical Trial: ACTG A5164:Immediate VS Delayed ART For Hiv-Infected Patients WINational Center For Research Resources2008
ACTG A5244: Effect Of Raltegravir On Viremia In HIV Subjects Infection On ARTNational Center For Research Resources2008
ACTG A5221: Immediate VS Deferred Antiretroviral Therapy For Hiv/TuberculosisNational Center For Research Resources2008
ACTG A5223: Sex Differences In Lopinavir/Ritonavir PharmacokineticsNational Center For Research Resources2006–2008
ACTG A5206: Impact On Dyslipidemia Of Adding Tenofovir To ARV Therapy In HIVNational Center For Research Resources2006–2008
Adult AIDS Clinical Trial Group Longitudinal Linked Randomized Trials ProtocolNational Center For Research Resources2005–2008
ACTG A5229: Uridine Supplementation In HIV LipoatrophyNational Center For Research Resources2007
ACTG A5220: Using GM-CSF To Improve Immune Response To Hepatitis B VaccineNational Center For Research Resources2007
ACTG A5209: Ezetimibe PLUS Statins To Lower Cholesterol In Hiv-Infected SubjectsNational Center For Research Resources2006–2007
ACTG A5202: Efavirenz Or Atazanavir With Ritonavir In Arv-Naive Subjects (AIDS)National Center For Research Resources2006–2007
ACTG A5175: Once-Daily ARV Therapy For HIV-1 In Resource-Limited SettingsNational Center For Research Resources2006–2007
ACTG A5211: SCH 417690 In Hiv-Infected, Treatment-Experienced SubjectsNational Center For Research Resources2005–2007
ACTG A5197: Antiretroviral Effect Of Immunization With The MRK AD5 HIV-1 GAG VANational Center For Research Resources2005–2007
ACTG A5178: Long-Term Antiviral Management Of HCV And HIV-1 Coinfected SubjectsNational Center For Research Resources2005–2007
ACTG A5164:Immediate VS Delayed ART For Hiv-Infected Patients With Acute OTNational Center For Research Resources2005–2007
ACTG A5142: Comparison Of Three Antiviral Regimens For Initial Therapy Of HIV-1National Center For Research Resources2005–2007
ACTG A5068: Withdrawl Of Antiretrovirals + HIV Vaccine In Subjects W/ Cd4>400National Center For Research Resources2005–2007
ACTG 362: Azithromycin Prophylaxis For Primary Prevention Of MAC In AIDSNational Center For Research Resources2005–2007
Aactg A5216: Cyclosporine A/Trizivir/Kaletra Versus Trizivir/Kaletra AloneNational Center For Research Resources2005–2007
ACTG A5163: Alendronate In HIV Subjects With Decreased Bone Mineral DensityNational Center For Research Resources2006
ACTG A5146: Therapeutic Drug Monitoring In Subjects With A Low Niq To Pis (AIDS)National Center For Research Resources2006
ACTG A5030: Valganciclovir For Pre-Emptive Therapy For Cytomegalovirus (AIDS)National Center For Research Resources2006
Effect Of Thymidine Analogue Change To Nucleoside-Sparing Regimen On Fat WastingNational Center For Research Resources2005–2006
ACTG A5173:Clearance Of HIV-1 In CD4+ Cells Of Subjects On T-20 PLUS Oral ARNational Center For Research Resources2005–2006
ACTG A5170: Predictors Of Disease Progression In Subjects WHO Discontinue ARTNational Center For Research Resources2005–2006
ACTG A5095: 3 Protease Inhibitor-Sparing Regimens For Initial Treatment Of HIVNational Center For Research Resources2005–2006
ACTG A5073:Twice Daily -V- Once Daily Haartand Self-Administered Versus DOTNational Center For Research Resources2005–2006
ACTG A5029: Human Papilloma Virus In Antiretroviral Naive HIV+ Women On HaartNational Center For Research Resources2005–2006
ACTG 371: 3tc/Zdv/Abc/Apv In Acute HIV Infection Or SeroconversionNational Center For Research Resources2005–2006
Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases2004–2006
Predictive Value Of Pk-Adjusted Phenotypic Susceptibility On Antiretroviral RESPNational Center For Research Resources2005
ACTG A5186: Effect Of Fish Oil And Fenofibrate On Triglyceride LevelsNational Center For Research Resources2005
ACTG A5163: Alendronate In HIV Subjects With Decreased Bone Mineral DensitNational Center For Research Resources2005
ACTG A5146: Therapeutic Drug Monitoring In Subjects With A Low Niq To PisNational Center For Research Resources2005
ACTG A5128: Obtaining Informed Consent To Use Stored Human Biological MaterialsNational Center For Research Resources2005
ACTG A5092s: Pharmacokinetic Effects Of Rbv On ZDV Or D4T Triphosphate FormationNational Center For Research Resources2005
ACTG A5030: Valganciclovir For Pre-Emptive Therapy For CytomegalovirusNational Center For Research Resources2005
Kinetic Interaction Of Apv, Efv, &A Second PINational Center For Research Resources2004
Evaluation Of Potential Pharmacokinetic Interactions Between Pis &CcbsNational Center For Research Resources2004
A Study To Evaluate The Effects Of Hydrochlorothiazide, Lisinopril, And AmoldopiNational Center For Research Resources2004
Discontinuation Antifungal For Cryptococcal MeningitisNational Center For Research Resources2000–2002
Safety, Pks, &Antifungal Effects Of Bms 207147 In HIV+ PatientsNational Center For Research Resources1999–2000